Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous DC Vaccine in Recurrent Respiratory Papillomatosis
NCT07317154Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Sep 2026
- Primary completion
- Jun 2027
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous HPV6 E6 and E7 peptide-loaded dendritic cell in recurrent respiratory papillomatosis (RRP), sponsored by Mayo Clinic. Primary endpoint: Number of participants with treatment-related adverse events at 20 months. Started Sep 2026; status: recruiting.
02
Drugs
autologous HPV6 E6 and E7 peptide-loaded dendritic cell
03
Conditions
recurrent respiratory papillomatosis (RRP)
Beyond the preview
Go deeper on NCT07317154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07317154.